<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633542</url>
  </required_header>
  <id_info>
    <org_study_id>MO 02/02 MM</org_study_id>
    <secondary_id>AIL 2002</secondary_id>
    <nct_id>NCT00633542</nct_id>
  </id_info>
  <brief_title>Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)</brief_title>
  <official_title>Thalidomide-Dexamethasone vs Alpha-Interferon-Dexamethasone as Maintenance Therapy After Thalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin Combination for</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Politecnica delle Marche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Politecnica delle Marche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is randomized, multicentre study aimed to compare a standard maintenance therapy with
      Interferon-Dexamethasone with an experimental therapy based on Thalidomide-Dexamethasone in
      patients with multiple myeloma who responded to ThaDD induction therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thalidomide has already been used as maintenance and/or consolidation after high-dose therapy
      followed by autologous stem cell transplantation. Despite a number of phase II and III
      studies the issues of right dose and duration of thalidomide and subsets of patients
      benefiting from it have not yet been settled We explored the maintenance therapy after
      thalidomide, dexamethasone and pegylated liposomal doxorubicin called ThaDD protocol.
      Patients with de novo or relapsed MM obtaining at least minor response after 4 to 6 ThaDD
      courses, were randomized to receive standard maintenance therapy with IFN 3 MU 3 times a week
      or an experimental maintenance therapy such as thalidomide 100 mg per day until relapse or
      intolerable side effects. Both groups also received pulsed dexamethasone 20 mg 4 days a
      month.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival safety</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>TD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>thalidomide-dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon-dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>100 mg/day orally until progression or severe toxicity</description>
    <arm_group_label>TD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon alpha</intervention_name>
    <description>3 MU 3 times a week until progression or severe toxicity</description>
    <arm_group_label>ID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with newly diagnosed or advanced multiple myeloma achieving at least a
             minimal response after induction with ThaDD regimen

          -  Written consent

        Exclusion Criteria:

          -  peripheral neuropathy &gt;= grade 2

          -  neutropenia &lt; 1000/mcl or thrombocytopenia &lt; 50000/mcl

          -  severe depression

          -  organ disfunction &gt; grade 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Offidani Massimo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>clinica di ematologia ospedali riuniti ancona università politecnica delle marche</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pietro Leoni, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>clinica di ematologia università politecnica delle marche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica di ematologia ospedali riuniti ancona università politecnica delle marche</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006 Oct 1;108(7):2159-64. Epub 2006 Jun 8.</citation>
    <PMID>16763209</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>March 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>March 4, 2008</last_update_submitted>
  <last_update_submitted_qc>March 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Offidani Massimo</name_title>
    <organization>Clinica di Ematologia Università Politecnica delle Marche</organization>
  </responsible_party>
  <keyword>thalidomide</keyword>
  <keyword>maintenance</keyword>
  <keyword>interferon</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>newly diagnosed multiple myeloma</keyword>
  <keyword>relapsed refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

